Abstract:Rheumatoid arthritis (RA) is a systemic, autoimmune disease that affects joints and extra-articular structures. In the last decade, the management of this chronic disease has dramatically changed with the introduction of several targeted mechanisms of action, such as tumor necrosis factor-α inhibition, T-cell costimulation inhibition, B-cell depletion, interleukin-6 blockade, and Janus kinase inhibition. Beyond its well-known hematopoietic role on the proliferation and differentiation of myeloid cells, granulocyte-monocyte colony-stimulating factor (GM-CSF) is a proinflammatory mediator acting as a cytokine, with a proven pathogenetic role in autoimmune disorders such as RA. In vitro studies clearly demonstrated the effect of GM-CSF in the communication between resident tissue cells and activated macrophages at chronic inflammation sites, and confirmed the elevation of GM-CSF levels in inflamed synovial tissue of RA subjects compared with healthy controls. Moreover, a pivotal role of GM-CSF in the perception of pain has been clearly confirmed. Therefore, blockade of the GM-CSF pathway by monoclonal antibodies directed against the cytokine itself or its receptor has been investigated in refractory RA patients. Overall, the safety profile of GM-CSF inhibitors seems to be very favorable, with a particularly low incidence of infectious complications. The efficacy of this new mechanism of action is comparable with main competitors, even though the response rates reported in phase II randomized controlled trials (RCTs) appear to be numerically lower than the response rates observed with other biological disease-modifying antirheumatic drugs already licensed for RA. Mainly because of this reason, nowadays the development program of most GM-CSF blockers for RA has been discontinued, with the exception of otilimab, which is under evaluation in two phase III RCTs with a head-to head non-inferiority design against tofacitinib. These studies will likely be useful for better defining the potential role of GM-CSF inhibition in the therapeutic algorithm of RA. On the other hand, the potential role of GM-CSF blockade in the treatment of other rheumatic diseases is now under investigation. Phase II trials are ongoing with the aim of evaluating mavrilimumab for the treatment of giant cell arteritis, and namilumab for the treatment of spondyloarthritis. Moreover, GM-CSF inhibitors have been tested in osteoarthritis and diffuse subtype of systemic sclerosis. This review aims to describe in detail the available evidence on the GM-CSF blocking pathway in RA management, paving the way to a possible alternative treatment for RA patients. Novel insights regarding the potential use of GM-CSF blockers for alternative indications will be also addressed.

GM-CSF-Dependent Inflammatory Pathways

GM-CSF in inflammation

GM-CSF engages multiple signaling pathways to enhance pro-inflammatory cytokine responses in human monocytes during infection

Evaluation of the effect of GM-CSF blocking on the phenotype and function of human monocytes

The Contribution of the Monocyte-Macrophage Lineage to Immunotherapy Outcomes

GM-CSF Monocyte-Derived Cells and Langerhans Cells As Part of the Dendritic Cell Family

Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders

IFNγ and GM-CSF control complementary differentiation programs in the monocyte-to-phagocyte transition during neuroinflammation

GM-CSF Grown Bone Marrow Derived Cells Are Composed of Phenotypically Different Dendritic Cells and Macrophages

Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update

Intracellular GM-CSF signaling in circulating monocytes, monocyte-derived macrophages, and human lung macrophages

Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases

GM-CSF: A Double-Edged Sword in Cancer Immunotherapy

Directs effects of granulocyte-macrophage colony stimulating factor (GM-CSF) on adaptive immunogenesis

GM-CSF Primes Proinflammatory Monocyte Responses in Ankylosing Spondylitis

Regulation of monocyte differentiation by specific signaling modules and associated transcription factor networks

GM-CSF receptor expression determines opposing innate memory phenotypes at different stages of myelopoiesis

Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects

Granulocyte-macrophage colony-stimulating factor: Conductor of the wound healing orchestra?

Effect of granulocyte colony stimulating factor in immunomodulation and role in intestinal immune homeostasis

Gene regulatory network of human GM-CSF secreting T helper cells